BOARD OF DIRECTORS

Dr. Johan Christenson

Partner of HealthCap. Prior to joining HealthCap in 2001, Dr. Christenson was with SEB Företagsinvest (the venture capital arm of SEB) to supervise its health care portfolio. He has senior management experience from Astra Pain Control as Project director and AstraZeneca as Global Product Director and member of the global therapy area management team of Pain & Inflammation. Dr. Christenson received his medical training at the Karolinska Institute and received his PhD in basic neuroscience in 1991. He served as a lecturer in neuroscience and also held a position as Assistant Dean at the Karolinska Institute Graduate School for two years. Dr. Christenson has four years of clinical specialist training in paediatrics and paediatric neurology.

Terry Gould, MBA

Mr. Gould is a Partner and Head of Venture/Growth Investments at Adams Street Partners, LLC. He invests in venture and growth-oriented companies with a focus on the healthcare space. Mr. Gould sits on the Boards of Directors of Aptinyx, Corvus Pharmaceuticals (NADSAQ: CRVS), Fusion Pharmaceuticals, LifeBond, Orbus Therapeutics, and Outpost Medicine. He is a Board Observer at Millendo. He is a former board member at CombiChem, INC Research, Incline Therapeutics, OncoMed (NADSAQ: OMED), and Proteus Digital Health. He is responsible for several other successful investments including Heartport, Jazz Pharmaceuticals, Naurex Pharmaceuticals, NxStage Medical, Pharmacyclics, Rempex Pharmaceuticals, Revivant, Spinal Dynamics and Vivant Medical.

Before joining in Adams Street in 1994, Mr. Gould was with Trinity Ventures, Ltd. and spent five years as a management consultant, including experience with the Boston Consulting Group, an international strategy consulting firm. He also has experience as a founder and executive in two successful entrepreneurial companies.

Terry is a graduate of Dartmouth College, BA and Stanford University Graduate School of Business, MBA.

Damian Lamb

Chair

Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over million in venture capital funds, and has been involved in deploying over million in 28 investments. He currently serves on the Boards of Affinium Pharmaceuticals Inc., Profound Medical Inc. and the Centre for Probe Development and Commercialization at McMaster University. He has served on the Board of Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.

Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences and was a judge for the BioNorth Top 10 Canadian Life Sciences Companies contest from 2000 to 2008.

Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with an M.S. in Molecular Neurobiology and also holds an MBA from Queen’s University.

Eran Nadav, PhD, MBA

Dr. Eran Nadav is an investor and a biopharma veteran. He has been with the investment firm TPG from 2007 to 2018, serving as Partner and Managing Director at the TPG Biotech fund in San Francisco. During his tenure at TPG, he led pharma and biotech deals across various geographies and stages of development. Currently he serves as Senior Advisor of TPG Biotech.

Prior to TPG, Dr. Nadav was Business Development Director at Eisai in New Jersey, where he evaluated and negotiated licensing and acquisition deals. Previously, Dr. Nadav worked for JJDC, the venture capital subsidiary of Johnson & Johnson. Earlier, he worked for Neurim Pharmaceuticals in a product development role.

Dr. Nadav holds a Ph.D. in Biochemistry, an M.Sc. magna cum laude, a B.Sc. magna cum laude, and an MBA from Tel Aviv University.

Dr. Nadav is currently a board member at Carisma Therapeutics, Fusion Pharmaceuticals, Nutrinia, Trevi Therapeutics, and Tevel Aerobotics Technologies. He is also a member at the Investment Committee at Lagunita Biosciences, a healthcare investment company and incubator. Representing TPG, Dr. Nadav was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) and Trevi Therapeutics. His other past investments and board roles include Collegium Pharmaceutical (Nasdaq: COLL), JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), ShangPharma (a China based CRO), and Eden Springs / Mey Eden (a leading European provider of workplace drinks solutions).

Alan O'Connell, PhD

Dr. O’Connell is a Partner at Seroba. He has a background in product and business development in the pharma/ biotech industry. Prior to joining the firm in 2003, Dr. O’Connell worked in a variety of roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and he also spent time at the Medicines and Healthcare Products Regulatory Agency (London). His previous venture capital experience was gained at Estée Lauder Investments (New York). Dr. O’Connell still sits on the scientific advisory board of the Lauder funded Alzheimer’s Drug Discovery Foundation. Dr. O’Connell graduated with a Ph.D. (neurophamacology) from the National University of Ireland, Galway (1994) and has a Master’s degree in pharmacology from the University of London (1990). He carried out post-doctoral neuroscience research at University College, Dublin and has published in several scientific journals. Dr. O’Connell also currently sits on the boards of Ario Pharma; Crescent Diagnostics; Heart Metabolics; Opsona Therapeutics; Prexton Therapeutics and Veryan Medical.

Robert M. Sutherland, Bsc, PhD

Dr. Robert Sutherland facilitates and advises FACIT in the identification of projects for early stage development and the engagement of market receptors and investor groups. Most recently, Dr. Sutherland was President of Varian Biosynergy, a subsidiary of Varian Medical Systems (Palo Alto, CA) from 1995-2006. He has held other senior positions in biomedical research and management. He was previously Vice-President and Executive Director, Life Sciences at SRI International (1988 to 1995), and the Associate Director of the Cancer Center for Experimental Therapeutics at the University of Rochester where he was a faculty member (1976-1988). Prior to that, he was on the faculty of the University of Western Ontario’s Department of Biophysics and a researcher at the Ontario Cancer Treatment and Research Foundation (1967 to 1976). During his career he has served as a consultant/reviewer for many national and international government research agencies, universities, industry, and scientific journals. He was recently a Consulting Professor of Radiation Oncology at Stanford University and is currently a member of several academic advisory groups and industry boards. He is also a member of many professional associations including the Radiation Research Society, American Society for Therapeutic Radiology and Oncology, and the American Association for Cancer Research. Dr. Sutherland holds a BSc (Hons Biology) from Acadia University and a PhD in Biophysics from the University of Rochester.

John Valliant, PhD

CEO

Dr. Valliant is Founder and Chief Executive Officer of Fusion Pharmaceuticals. Dr. Valliant has been instrumental in securing both investment and scientific and medical collaborations with the industrial and academic partners of Fusion.

Prior to Fusion, Dr. Valliant founded the Centre for Probe Development and Commercialization (CPDC), a radiopharmaceutical research and development centre of excellence established in 2008 through funding from the Federal and Provincial governments, industry and academic partners. The CPDC is focused on discovering, developing and distributing the next generation of molecular imaging probes. The CPDC also plays an important role in Canada’s health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals and clinics nationally and internationally.

Dr. Valliant is also a Professor in the Department of Chemistry and Chemical Biology at McMaster University. His current research focuses on developing new radiolabeling methods and compound discovery strategies to create clinically relevant molecular imaging probes and therapeutic radiopharmaceuticals.

In 2009, Dr. Valliant was selected as one of Canada’s Top 40, Under 40, a distinction that recognizes his work at CPDC and McMaster University to advance molecular imaging probe technologies, improve patient care and spur economic growth through commercialization of Canadian technologies. In 2015, he received the Brockhouse Canada Prize for Interdisciplinary Research in Science and Engineering from NSERC, recognizing his contribution to a team of researchers from physics, chemistry and nuclear medicine, who developed breakthrough technology that uses hospital-based cyclotrons to produce critical medical isotopes.

Dr. Valliant completed his PhD at McMaster University, and followed with a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).

Asish K. Xavier, PhD, MBA

Dr. Xavier is with Johnson & Johnson Development Corporation (JJDC) and is based in the Johnson & Johnson Innovation Center in California. Dr. Xavier focuses on venture investments in biotechnology and diagnostics. Dr. Xavier joined JJDC in 2004, and has invested in over a dozen biotech and diagnostics deals.

Dr. Xavier previously worked in business development at BioRexis Pharmaceutical Corporation which was acquired by Pfizer in 2007. While at BioRexis, he assisted the company in raising a million second round of financing. Dr. Xavier has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc.

Dr. Xavier received a PhD from the University of Houston in Chemical Engineering, and a MBA from the Wharton School of the University of Pennsylvania, where he graduated with honors. He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Dr. Xavier was a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.